BIIB
reuters.dev
http://www.google.com/url?source=finance&q=http%3A%2F%2Fwww.reuters.com%2Ffinance%2Fstocks%2FBIIB.O%2Fkey-developments%2Farticle%2F2669707&ei=oIaaUqDjE4qw0AGZAw&usg=AFQjCNEgoC4GJ-VJfvHjMQferVT2dMSWkA
Biogen Idec Inc's Lou Gehrig's Disease Drug Fails In Key Trial-Reuters
Thursday, 3 Jan 2013 12:04pm EST
Reuters reported that Biogen Idec's experimental drug to combat amyotrophic lateral sclerosis, commonly called Lou Gehrig's disease in the United States, failed to work in an important trial and the Company said it would stop development of he treatment. The drug, dexpramipexole, had shown promise and seemed to work against ALS in a mid-stage clinical trial in 2011, creating hope for patients suffering from the progressive, fatal disease, who currently have few options.Â 
